Key Takeaways:
- Researchers from the Sbarro Institute, the National Cancer Institute – Pascale Foundation, and the University of Pisa have discovered a new approach to designing molecules with potential antitumor activity using artificial intelligence (AI)
- The study employed sophisticated AI algorithms to identify new molecules capable of inhibiting the enzymatic activity of the CDK9 protein, a promising therapeutic target in the fight against cancer
- The researchers used machine learning to carry out a large-scale virtual screening and identified 14 candidate molecules, two of which showed significant cytotoxic activity and reduced the viability of tumor cells
- The study demonstrates the potential of AI in accelerating the development of new anticancer drugs and highlights the importance of integrating human expertise with advanced technologies in cancer research
Introduction to the Study
A groundbreaking study published in the journal Biomolecules has revealed the potential of artificial intelligence (AI) in designing new molecules with antitumor activity. The research, conducted by a team of scientists from the Sbarro Institute, the National Cancer Institute – Pascale Foundation, and the University of Pisa, has shown that AI can be a powerful tool in the fight against cancer. As Prof. Antonio Giordano, Founder and Director of the Sbarro Health Research Organization (SHRO), notes, "Artificial intelligence is proving to be one of the fundamental tools for basic and applied research, thanks to its enormous analytical and predictive capabilities." The study focused on the CDK9 protein, an enzyme involved in regulating gene transcription and cell proliferation, which has emerged as a promising therapeutic target in cancer treatment.
The Role of CDK9 in Cancer
The CDK9 protein has been found to play a crucial role in the development and progression of cancer. As Prof. Giordano explains, "CDK9 has progressively emerged as one of the most promising therapeutic targets in the fight against cancer, as its hyperactivation is often associated with uncontrolled tumor cell growth and their ability to survive conventional treatments." The researchers used AI algorithms to design and identify new molecules capable of inhibiting the enzymatic activity of CDK9, with the goal of developing new anticancer drugs. By targeting CDK9, the researchers aim to prevent the growth and survival of cancer cells, ultimately leading to more effective cancer treatments.
The Use of Artificial Intelligence in Research
The study highlights the potential of AI in accelerating the development of new anticancer drugs. As Prof. Tiziano Tuccinardi of the University of Pisa notes, "AI makes it possible to drastically reduce the time and costs of the initial drug discovery phase, while at the same time increasing the likelihood of identifying truly effective compounds." The researchers used machine learning, a specific branch of AI, to carry out a large-scale virtual screening of molecules and identify those with potential antitumor activity. This approach allowed the researchers to quickly and efficiently identify promising molecules, which were then subjected to experimental testing.
Experimental Testing and Results
The selected molecules were evaluated in cellular models of cervical carcinoma and breast cancer, two tumor types of major clinical relevance. The results showed that two of the compounds were able to exert significant cytotoxic activity and reduce the viability of tumor cells, demonstrating promising therapeutic potential. As Dr. Luigi Alfano, a researcher at the National Cancer Institute of the Pascale Foundation, notes, "We have launched a new Drug Discovery project focused on the identification of new molecules, both of natural and synthetic origin, designed through artificial intelligence. This pathway is already producing very encouraging results and lays solid foundations for the development of new potential anticancer drugs."
Conclusion and Future Directions
The study demonstrates the potential of AI in accelerating the development of new anticancer drugs and highlights the importance of integrating human expertise with advanced technologies in cancer research. As Prof. Giordano notes, "Experimental validation by humans remains a crucial and irreplaceable phase of the entire scientific process." The researchers plan to continue using AI to identify new molecules with potential antitumor activity and to develop new anticancer drugs. With the help of AI, the researchers hope to make significant progress in the fight against cancer and improve treatment options for patients. As Prof. Tuccinardi notes, "This scientific work has confirmed for us how the use of artificial intelligence in research can be fundamental for the identification of new molecules to be used in the fight against cancer."
https://www.newswise.com/articles/artificial-intelligence-designs-anti-cancer-molecules-to-target-cdk9